ID22975A - METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids - Google Patents

METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids

Info

Publication number
ID22975A
ID22975A IDW991185A ID991185A ID22975A ID 22975 A ID22975 A ID 22975A ID W991185 A IDW991185 A ID W991185A ID 991185 A ID991185 A ID 991185A ID 22975 A ID22975 A ID 22975A
Authority
ID
Indonesia
Prior art keywords
corticosteroids
compositions
methods
modulate response
modulate
Prior art date
Application number
IDW991185A
Other languages
Indonesian (id)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID22975A publication Critical patent/ID22975A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW991185A 1997-03-18 1998-03-12 METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids ID22975A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30

Publications (1)

Publication Number Publication Date
ID22975A true ID22975A (en) 1999-12-23

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991185A ID22975A (en) 1997-03-18 1998-03-12 METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
CA2276420A1 (en) * 1997-10-31 1999-05-14 Terry Strom Use of anti-il-12 antibodies in transplantation rejection
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CA2323439A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
DK1137766T3 (en) * 1998-12-09 2006-01-30 Protein Design Labs Inc Use of IL-12 antibodies to treat psoriasis
CN1346344A (en) 1999-03-16 2002-04-24 西托维亚公司 Substituted 2-aminobenzamide caspase ihibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
ATE409688T1 (en) 1999-08-27 2008-10-15 Cytovia Inc SUBSTITUTED ALPHA-HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE
AU7127600A (en) * 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
WO2001097815A2 (en) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
DE60224004T2 (en) * 2001-01-29 2009-07-23 Laboratoires Serono S.A., Coinsins USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF HEART DISEASES
DK1425028T3 (en) * 2001-05-16 2010-03-01 Yeda Res & Dev Use of IL-18 inhibitors to treat or prevent sepsis
SG2011076551A (en) 2001-06-26 2015-08-28 Amgen Inc Antibodies to opgl
RU2322984C2 (en) * 2001-10-05 2008-04-27 Комбинаторкс, Инкорпорейтед Combinations for treating immuno-inflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
EP1553955A4 (en) * 2002-09-24 2008-11-05 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JPWO2005110450A1 (en) * 2004-05-17 2008-03-21 学校法人慶應義塾 Pharmaceutical composition and method of treatment
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1808446T3 (en) 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
WO2008048770A1 (en) * 2006-10-17 2008-04-24 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
BRPI0806605A2 (en) 2007-01-16 2011-09-06 Abbott Lab Methods To Treat Psoriasis
MX2009010361A (en) 2007-03-29 2009-10-16 Abbott Lab Crystalline anti-human il-12 antibodies.
RU2497545C2 (en) 2008-03-18 2013-11-10 Эбботт Лэборетриз Method of treating psoriasis (versions)
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EA201270784A1 (en) 2010-11-24 2013-04-30 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" MONOTHERAPE TREATMENT COMPOSITIONS OF SELECTIVE LIPOPHIL AND BETA-AGONIST OF LONG ACTION AND METHODS OF COSMETIC TREATMENT FOR OBESITY AND COUNTER-ROOTING
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
ATE92762T1 (en) * 1989-09-08 1993-08-15 Glaxo Group Ltd MEDICATION.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
KR19980703850A (en) * 1995-04-14 1998-12-05 그레이엄브레레톤 Weighing Aspirator for Beclomethasone Dipropionate

Also Published As

Publication number Publication date
WO1998041232A3 (en) 2000-10-05
SK122199A3 (en) 2000-12-11
ES2146192T1 (en) 2000-08-01
SI20110A (en) 2000-06-30
BG103808A (en) 2000-07-31
AU734756B2 (en) 2001-06-21
IL131815A0 (en) 2001-03-19
EP0998300A1 (en) 2000-05-10
AU6760498A (en) 1998-10-12
HUP0104439A3 (en) 2002-08-28
NO994506D0 (en) 1999-09-17
DE998300T1 (en) 2001-03-01
JP2002504091A (en) 2002-02-05
TR199902615T2 (en) 2000-03-21
NZ337769A (en) 2002-09-27
WO1998041232A2 (en) 1998-09-24
NO994506L (en) 1999-11-17
PL336464A1 (en) 2000-06-19
KR20000076420A (en) 2000-12-26
CN1269722A (en) 2000-10-11
HUP0104439A2 (en) 2002-04-29
BR9810409A (en) 2000-08-22
CA2282845A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
ID22975A (en) METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids
ID24284A (en) ABSORBEN PRODUCTS AND EQUIPMENT AND METHODS TO PRODUCE SUCH ABSORBEN PRODUCTS
ID17437A (en) METHODS AND COMPOSITIONS TO MAKE LIGHT SKIN
ID22389A (en) COMPOSITION AND METHODS TO REDUCE OCCULAR HYPERTENSION
ID19588A (en) ESTER AND HETEROSICLIC AMIDA
ID21935A (en) HAIR COLOR PROCESS AND COMPOSITION
ID19422A (en) PYRIDINA AND SUBSTITUTED BIFENYL
ID20400A (en) COMPOSITION AND METHODS FOR INHIBITING AGING DUE TO LIGHT ON SKIN
FI972496A (en) Fusarium isolate and lipases, cutinases and enzyme compositions derived therefrom
ID23953A (en) 5-ALKIL-2-ARILAMINOFENILASETAT ACID AND ITS DECLARATION
ID22708A (en) GENERAL DEVELOPMENT AND METHODS
FI962932A (en) Modulators of anchor protein function
ID17233A (en) METHODS AND [EQUIPMENT TO CONTROL TANK EXTENSION TANK AND TEMPERATURE TANK
FR2772599B1 (en) COSMETIC COMPOSITION AND USES THEREOF
ID24828A (en) PHARMACY COMPOSITIONS OF TIZOKSIANIDA AND NITAZOKSANIDA
ID16889A (en) ALKILAMINOBENZOTIAZOL AND BENZOKSAZOL COMPOUNDS
ID18456A (en) PRODUCTION-JOINT 6-AMINOCAPRONITRIL AND HEXSAMETYLENADIAMINA
ID16923A (en) BITUMENT COMPOSITIONS AND THE PROCESS OF MAKING
ID30135A (en) COMPOSITIONS AND METHODS TO CONTROL INSECTS
ID20911A (en) CIGARETTE AS WELL AS THE METHOD AND EQUIPMENT TO MAKE CIGARETTE
ID25848A (en) COMPOSITIONS AND METHODS OF SYNERGIC HERBISIDES
FR2772608B1 (en) COSMETIC COMPOSITION AND USES THEREOF
ID18459A (en) PRODUCTION-JOINT 6-AMINOCAPRONITRIL AND HEXSAMETYLENADIAMINA
ID24463A (en) METHOD OF IMPROVING THE AVAILABILITY OF PHYSOFENADIN AND ITS DECLARATION
ID21862A (en) COMPOSITIONS OF INSECTICIDE AND MITISIDE